Market Scope®

2017 Glaucoma Pharmaceuticals Report
A Global Market Analysis for 2016 to 2022

90 CHARTS AND TABLES

190 COMPREHENSIVE PAGES

26 COMPANY PROFILES

8 GEOGRAPHIC AND ECONOMIC BREAKOUTS

9859 Big Bend Blvd. Suite 202 | St. Louis, MO 63122 | 314.835.0600 | market-scope.com
The outlook for the glaucoma pharmaceuticals market is growing more positive as new products with new mechanisms of action begin commercialization or enter the final stages of the regulatory approval process. Market Scope estimates the glaucoma pharmaceuticals market will reach $5.3 billion in 2022. However, prospects vary considerably by region.

4.4 Billion in Manufacturer Revenues in 2017

- Branded Prostaglandin Analogs / Prostamides: 34%
- Fixed Combo Drugs: 32%
- Alpha Agonists: 9%
- Generic Prostaglandins: 8%
- Carbonic Anhydrase Inhibitors: 7%
- Other: 1%

What’s New

Author: Peter Downs
Released: August 2017

2017 Glaucoma Pharmaceuticals Report

Market Scope’s 2017 Glaucoma Pharmaceuticals Report provides in-depth coverage of commercialized and investigational glaucoma medications in the market.

Four Disease Categories Are Analyzed In This Report:
- Primary Open-angle Glaucoma (POAG)
- Primary Angle-closure Glaucoma (PACG)
- Other Secondary OAG and ACG
- Ocular Hypertension (OHT)

Each Market Segment Includes:
- An Analysis of Market Competitors and Five-Year Forecasts for Market Performance
- Overview of Glaucoma
- Prevalence of Glaucoma and Diagnosed Cases
- Glaucoma Care Providers
- Diagnosing Glaucoma
- Treating Glaucoma
- Glaucoma Medications in the Marketplace
- Development Pipeline for Glaucoma Rx
- Adjunctive Drugs Used in Glaucoma Surgery
- 26 Company Profiles
- 54 Color Tables and 36 Color Figures
Our report on the glaucoma pharmaceuticals market, now in its fourth edition, is a leading industry source for accurate and relevant information on all aspects of the glaucoma pharmaceuticals market. The glaucoma pharmaceuticals market is one of the largest and most complex market segments in ophthalmology with a variety of drug classes, as well as proprietary and generic versions of many drugs. Current ocular hypotensive medication classes used to treat glaucoma were developed 20 years ago or more, and generic versions of these medications are now in widespread use.

> This report includes market data for 2016, and we forecast market performance through 2022.

How to Order

Order your 2017 Glaucoma Pharmaceuticals Report now at www.market-scope.com or contact us directly via email or phone.

<table>
<thead>
<tr>
<th>ENTERPRISE LICENSE</th>
<th>SINGLE-USER LICENSE</th>
<th>ONE-YEAR SUBSCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017 Glaucoma</td>
<td>2017 Glaucoma</td>
<td>Ophthalmic Market</td>
</tr>
<tr>
<td>Pharmaceuticals</td>
<td>Pharmaceuticals</td>
<td>Perspectives Newsletter</td>
</tr>
<tr>
<td>Report</td>
<td>Report</td>
<td></td>
</tr>
<tr>
<td>$9,750</td>
<td>$6,500</td>
<td>$900</td>
</tr>
<tr>
<td>(Price includes a</td>
<td>Additional Printable</td>
<td>(Outside the US —</td>
</tr>
<tr>
<td>printable PDF and</td>
<td>Electronic PDF</td>
<td>$950)</td>
</tr>
<tr>
<td>supplemental Excel</td>
<td>Additional Paper</td>
<td></td>
</tr>
<tr>
<td>file with all the</td>
<td>Copy</td>
<td></td>
</tr>
<tr>
<td>tables and figures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>in the report)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

314.835.0600  | info@market-scope.com

Please add $50 for shipping if ordering from outside the US.

Our Process

Market Scope’s industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective ophthalmic experience and each data point is driven by a combination of sources, including the following:

- Our proprietary global disease population and demographic models
- Twenty years and counting of ophthalmologist survey data
- Analysis of company published financial reports
- Focused coverage of ophthalmic scientific research, business news, and other activities
- Attendance and participation in major, worldwide ophthalmic meetings
- Interviews and long-standing relationships with company executives and practicing ophthalmologists
### TABLE OF CONTENTS

**INTRODUCTION**
- Scope of Report
- Methodology
- About the Author
- The Report at a Glance

**EXECUTIVE SUMMARY**
- Glaucoma and its Prevalence
- The Global Market
- Current Market Competitors
- Factors Shaping the Marketplace

**ABOUT GLAUCOMA**
- Open-Angle Glaucoma (OAG)
- Normal-Tension Glaucoma as a Subset of OAG
- Exfoliation Glaucoma (XFG) as a Subset of OAG
- Angle-Closure Glaucoma (ACG)
- Exfoliation Glaucoma (XFG) as a Subset of OAG
- Normal-Tension Glaucoma as a Subset of OAG
- Open-Angle Glaucoma (OAG)

**DIAGNOSING GLAUCOMA**
- Tonometry
- Pachymetry
- Perimetry or Visual Field Testing
- Ophthalmoscopy
- Fundus Photography
- Optical Coherence Tomography
- Confocal Scanning Laser Ophthalmoscopy
- Scanning Laser Polarimetry
- Glaucoma Scope Examination
- Slit Lamp Biomicroscopy
- Gonioscopy with Contact Lens
- Ultrasound Biomicroscopy
- Diagnosed Disease Rates
- Growth in Glaucoma’s Diagnosis

**TREATING GLAUCOMA**
- Treatment Modalities
- Rx Medications
- Treating Open-Angle Glaucoma
- Treating IOP in Ocular Hypertension Patients
- Treating Exfoliation/Exfoliation Glaucoma (XFG/PFG)
- Treating Angle-Closure Glaucoma
- Limitations of Current Medications
- Referral to Glaucoma Specialists
- Laser and Surgery
- Traditional Surgical Approaches
- Newer Surgical Approaches
- Traditional Medicine and Alternative Therapies

**GLAUCOMA MEDICATIONS IN THE MARKETPLACE**
- Rho Kinase Inhibitor
- Prostaglandins Analogs and Prostaglandins
- Synthetic Docosanoids
- Beta Blockers
- Alpha Agonists
- Selective Alpha Adrenergic Agonists
- Nonselective Alpha Adrenergic Agonists
- Carbonic Anhydrase Inhibitors
- Cholinergic Agonists
- Fixed Combination Medications
- Comparative IOP Reduction: Brands and MOAs
- The Market Mix: Original Medications and Generics
- Branded Proprietary IOP-lowering Medications
- Generic IOP-lowering Medications
- Branded Generics

**FORECAST FOR THE GLAUCOMA PHARMA MARKET**
- Prospects in Wealthy Nations
- Economic Shifts in Emerging Markets
- Changing Role of Glaucoma Procedures
- Global Market for Glaucoma Medications
- The Global Market by Medication Class
- The Global Market by Competitor
- Forecast for the Global Glaucoma Rx Market
- US Market for Glaucoma Medications
- Western Europe’s Market for Glaucoma Medications
- Japan’s Market for Glaucoma Medications
- China’s Market for Glaucoma Medications
- India’s Market for Glaucoma Medications
- Latin America’s Market for Glaucoma Medications
- ROW’s Market for Glaucoma Medications

**DEVELOPMENT PIPELINE FOR GLAUCOMA PHARMA**
- Prostaglandin Analogs
- Bausch + Lomb/Nicov: Vyzulta
- Nicov: NCX 470
- Ono Pharmaceutical/Santen: Sepetaprost
- Santen/Novagali Pharma: Catioprost
- Rho-kinase Inhibition
- Aerie Pharmaceuticals: Rhopressa
- pH Pharma: PHP-201
- Discontinued Rho-Kinase Inhibitors
- Adenosine Receptor Agonists and Antagonists
- Inotek Pharmaceuticals: Trabodenoson
- Acorn Biomedical: ACN-1052
- Discontinued Adenosine Receptor Agonists
- EP Receptor Agonists
- Santen: DE-117 (omidinepap isopropyl)
- Discontinued EP Receptor Agonsists
- Additional IOP-lowering Compounds
- Sylenis: Bamosiran (SYL-040012)
- Neuroprotection and Neuroregeneration
- Quark Pharmaceuticals: QPI-1007
- Merz Pharmaceuticals: MRZ-99030

**MARKETPLACE**
- Cholinergic Agonists
- Carbonic Anhydrase Inhibitors
- Nonselective Alpha Adrenergic Agonists
- Selective Alpha Adrenergic Agonists
- Beta Blockers
- Synthetic Docosanoids
- Adenosine Receptor Agonists and Antagonists
- Rho-kinase Inhibition
- Prostaglandin Analogs
- Other Neuroprotective Compounds
- Discontinued Candidates
- Fixed Combinations of Agents
- Aerie Pharmaceuticals: Rodlantan
- Inotek: Trabodenoson Plus Latanoprost
- Laboratoires Théa: T2347
- New Drug Delivery Technologies
- Clinical Stage Programs
- Preclinical Programs
- Review of Investigational Technologies

**ADJUNCTIVE DRUGS USED IN GLAUCOMA SURGERY**
- Compounds Used Off Label
- Mobius Therapeutics’ Mitosol
- Altacor/Esperante’s ALT 401 (Trilanilast)

**COMPANY PROFILES**
- Aerie Pharmaceuticals
- Akorn
- Allergan, PLC
- Amorphex Therapeutics LLC
- Bausch + Lomb
- Envisia Therapeutics
- Inotek Pharmaceuticals Corporation
- Laboratoires Théa
- Laboratorios Sophia, SA de CV
- Matti Therapeutics, Inc.
- Merz GmbH & Co. KGaA
- Mobius Therapeutics LLC
- Neurotech Pharmaceuticals, Inc.
- Nicov
- Novartis
- Ocular Therapeutics
- Ono Pharmaceutical Co., Ltd.
- Otsuka Pharmaceutical Co., Ltd.
- Pfizer
- pH Pharma
- Quark Pharmaceuticals
- Santen Pharmaceutical Co., Ltd.
- Sun Pharmaceutical Industries, Inc.
- Sylenis
- Teva
- Võsi Ltd.

---

**About Us**

Market Scope is recognized as the leading source for accurate and timely industry information in ophthalmology.

We have been conducting primary research and producing comprehensive reports on ophthalmic markets since 1996. Our data, analysis, and forecasts serve as starting points for many annual planning cycles, strategic plans, acquisition analyses, and return-on-investment decisions in the industry. In addition, our information is routinely included in annual reports, SEC filings, and investor presentations by leading ophthalmic companies.